FilingSEC EDGAR6-K
Cellectis Presents Preclinical Data for Hypertriglyceridemia Candidate .HEAL-101
· SEC accepted
StagePreclinical
Filing content
The company reported preclinical data showing APOC3 gene editing and triglyceride reduction, with preliminary clinical data from a Phase 1 trial in China expected in the second half of 2027.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…